
{
    "Variants Include": [
        {
            "Gene": "SNCA",
            "variants": [
                {
                    "HGVS": "NM_000345.4:c.157G>A",
                    "cDNA Change": {
                        "transcript": "NM_001143661.2",
                        "ref": "G",
                        "alt": "A",
                        "position": "157"
                    },
                    "Protein Change": {
                        "ref": "A",
                        "alt": "T",
                        "position": "53"
                    },
                    "Description in input context": "A53T"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease",
        "MONDO": "MONDO:0005180"
    },
    "Experiment Method": [
        {
            "Assay Method": "Immunohistochemistry",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Postmortem brain tissue",
                "Description": "Postmortem brain tissue from a patient in the Contursi kindred carrying the A53T α-syn gene mutation."
            },
            "Readout type": "Qualitative",
            "Readout description": [
                {
                    "Variant": "NM_001143661.2:c.157G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "Insoluble filamentous α-syn lesions were detected in almost all brain regions examined. Significant accumulations of filamentous insoluble tau protein also were detected in some brain regions."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Immunostaining of brain sections for α-syn was optimized by pretreating sections in 88% formic acid (FA) for 30 min."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Absence of insoluble α-syn and tau in brain regions.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Detection of insoluble filamentous α-syn and tau in brain regions.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "Western Blot",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Frozen brain tissue",
                "Description": "Frozen brain tissue from cingulate cortex, midfrontal cortex, cerebellum and hippocampus, and 10 different subcortical areas."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_001143661.2:c.157G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "A significant portion of α-syn in cingulate cortex from case IX-51 is extractable only with SDS, and a larger pool is solubilized only with FA, indicating insoluble α-syn. Western blots with nSyn14 antibody confirmed the presence of nitrated α-syn in FA extracts of hippocampus and cingulate cortex."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Cingulate cortex from a sporadic PD case without clinical dementia served as a positive control for insoluble α-syn."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "Cingulate cortex from a pathologically normal brain served as a negative control."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Levels of α-syn and tau comparable to healthy controls (e.g., α-syn fully extractable in HS buffer).",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Increased levels of insoluble and nitrated α-syn and tau compared to healthy controls.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "Electron Microscopy",
            "Material used": {
                "Material Source": "Patients Derived Material",
                "Material Name": "Brain sections and sarkosyl-insoluble material",
                "Description": "Selected brain sections and sarkosyl-insoluble material from hippocampus and dorsal pons."
            },
            "Readout type": "Qualitative",
            "Readout description": [
                {
                    "Variant": "NM_001143661.2:c.157G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "Immuno-EM studies of inclusions labeled with antibodies to α-syn revealed characteristic spheroids that frequently showed a filamentous ultrastructure. Inclusions containing tau fibrils were also detected in situ. Isolated sarkosyl-insoluble material from hippocampus and dorsal pons contains α-syn and tau filaments."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "Antibodies to α-syn (Syn 303) and tau (PHF-1) were validated by detecting known filamentous structures in other neurodegenerative diseases."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Absence of filamentous structures and inclusions.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Presence of filamentous structures and inclusions containing α-syn and tau.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "In vitro fibrillization assays",
            "Material used": {
                "Material Source": "Recombinant protein",
                "Material Name": "Recombinant tau T40, wild-type α-syn, and A53T mutant α-syn",
                "Description": "Polymerization of bacterial recombinant tau T40 with recombinant wild-type (WT) and A53T mutant α-syn."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_001143661.2:c.157G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "Fibril assembly was much faster for A53T compared to WT α-syn, and coassembly experiments showed that the rates of assembly of α-syn and tau were accelerated when A53T instead of WT α-syn was used."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "Yes",
                "Description": "n = 4 samples"
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "WT α-syn served as a positive control for normal fibrillization rates."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "Nonfibrillogenic D71–82 mutant α-syn and fibrillogenic amyloid Aβ(1–40) peptide served as negative controls for tau fibrillization promotion."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "N.D."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "Fibrillization rates comparable to wild-type α-syn",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "Accelerated fibrillization rates compared to wild-type α-syn",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}